...
首页> 外文期刊>Naunyn-Schmiedeberg's Archives of Pharmacology >Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium.
【24h】

Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (-)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium.

机译:磷酸二酯酶PDE3和PDE4共同控制(-)-CGP12177的正性肌力作用,但不能控制变时性作用,尽管PDE4引起大鼠心房窦房性心动过缓。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Acting through a low-affinity site of the beta(1)-adrenoceptor (beta(1L)AR), CGP12177 causes sinoatrial tachycardia and positive inotropic effects in left atrium but not in the ventricle of the rat. However, inhibition of either PDE3 or PDE4 also uncovers positive inotropic effects of CGP12177 in ventricle, but whether these phosphodiesterases also control the atrial agonist effects of CGP12177 was unknown. We, therefore, investigated the effects of the PDE3-selective inhibitor cilostamide (300 nM) and PDE4 inhibitor rolipram (1 microM) on the (-)-CGP12177-evoked increases of sinoatrial beating rate and force of paced left atria of the rat. Rolipram (n = 8) increased basal sinoatrial rate by 27 +/- 5 bpm but cilostamide (n = 8) had no effect. The chronotropic potency of (-)-CGP12177 (-logEC(50)M = 7.5) was not changed by rolipram and cilostamide or their combination. (-)-CGP12177 increased left atrial force with intrinsic activity 0.25 compared to (-)-isoprenaline. Rolipram (n = 8) and cilostamide (n =8) did not change basal force of left atria but concurrent rolipram + cilostamide (n = 8) increased force by 52 +/- 9% of the effect of 200 microM (-)-isoprenaline. Neither rolipram nor cilostamide affected the inotropic potency of (-)-CGP12177 (-logEC(50)M = 7.4) but concurrent rolipram + cilostamide caused potentiation (-logEC(50)M = 8.2) and converted (-)-CGP12177 into a full agonist compared to (-)-isoprenaline. Cyclic AMP appears to maintain sinoatrial rate and PDE4 elicits bradycardia through hydrolysis of cAMP in a compartment distinct from the beta(1L)AR-induced cAMP compartment through which (-)-CGP12177 causes tachycardia. In contrast to the (-)-CGP12177-evoked tachycardia, not controlled by PDE3 and PDE4, these isoenzymes jointly reduce (-)-CGP12177-evoked increases of left atrial contractility through beta(1L)AR.
机译:通过β(1)-肾上腺素受体(β(1L)AR)的低亲和力位点起作用,CGP12177引起窦房性心动过速和正性肌力作用在大鼠左心房,但不在大鼠心室。然而,对PDE3或PDE4的抑制也揭示了CGP12177在心室中的正性肌力作用,但是这些磷酸二酯酶是否也控制CGP12177的心房激动剂作用尚不清楚。因此,我们研究了PDE3选择性抑制剂西洛酰胺(300 nM)和PDE4抑制剂rolipram(1 microM)对(-)-CGP12177引起的大鼠窦房跳动率和大鼠左心房搏动力的影响。咯利普兰(n = 8)使基础窦房率增加27 +/- 5 bpm,但西洛他酰胺(n = 8)无效。咯利普兰和西洛他酰胺或其组合未改变(-)-CGP12177(-logEC(50)M = 7.5)的变时性效力。与(-)-异丙肾上腺素相比,(-)-CGP12177增加的左心房内在活性为0.25。咯利普兰(n = 8)和西洛酰胺(n = 8)不会改变左心房的基础力,但同时咯利普兰+西洛司他胺(n = 8)使力增加了200 microM(-)-的52 +/- 9%异丙肾上腺素。咯利普兰和西洛他酰胺均未影响(-)-CGP12177的正性肌力(-logEC(50)M = 7.4),但同时出现的咯利普兰+西洛司他胺引起增强作用(-logEC(50)M = 8.2)并将(-)-CGP12177转化为与(-)-异丙肾上腺素相比,完全激动剂。环状AMP似乎可以维持窦房率,并且PDE4通过在不同于β(1L)AR诱导的cAMP区室的cAMP水解中引起cAMP的水解而引起心动过缓,β-(1)-CGP12177引起心动过速。与不受PDE3和PDE4控制的(-)-CGP12177诱发的心动过速相反,这些同功酶通过β(1L)AR共同降低(-)-CGP12177诱发的左心房收缩力的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号